Literature DB >> 22993561

Extra-nodal natural killer/T cell lymphoma, nasal-type, treated by concurrent chemoradiotherapy.

Nobuhiko Yoshikawa1, Taisuke Inomata, Taiju Shinbo, Masatsugu Takahashi, Yasuo Uesugi, Yoshihumi Narumi.   

Abstract

The present study reports on a case of extra-nodal natural killer/T cell lymphoma, nasal-type (ENKL), stage IIEA, in a 50-year-old woman who presented with a white tumor on a refractory ulcer on the gum. Concurrent chemoradiotherapy was administered, and effected a partial response. However, tumor recurrence was observed 5 months after the final diagnosis, and the patient succumbed 1 month after recurrence. Although a definitive treatment for ENKL has yet to be established due to its rarity, radiation therapy (RT) is crucial to therapy, as ENKL is very sensitive to RT. However, treatment with radiation levels above 50 Gy with an extended RT field are required for a favorable outcome. The development of novel chemotherapy regimens may therefore be useful. Additionally, autologous or allogenic hematopoietic stem-cell transplantation may prove to be a promising approach.

Entities:  

Year:  2010        PMID: 22993561      PMCID: PMC3445944          DOI: 10.3892/etm_00000070

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  10 in total

1.  Treatment outcome of angiocentric T-cell and NK/T-cell lymphoma, nasal type: radiotherapy versus chemoradiotherapy.

Authors:  Kyubo Kim; Eui Kyu Chie; Chul Woo Kim; Il Han Kim; Charn Il Park
Journal:  Jpn J Clin Oncol       Date:  2005-01       Impact factor: 3.019

2.  Extranodal natural killer/T-cell lymphoma, nasal type: the significance of radiotherapeutic parameters.

Authors:  Koichi Isobe; Takashi Uno; Jun-ichi Tamaru; Hiroyuki Kawakami; Naoyuki Ueno; Hisashi Wakita; Jun-ichi Okada; Jun Itami; Hisao Ito
Journal:  Cancer       Date:  2006-02-01       Impact factor: 6.860

3.  Localized aggressive non-Hodgkin's lymphoma of the nasal cavity: a survey by the Japan Lymphoma Radiation Therapy Group.

Authors:  N Shikama; H Ikeda; S Nakamura; M Oguchi; K Isobe; S Hirota; M Hasegawa; K Nakamura; K Sasai; N Hayabuchi
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-12-01       Impact factor: 7.038

4.  The world health organization classification of malignant lymphomas in japan: incidence of recently recognized entities. Lymphoma Study Group of Japanese Pathologists.

Authors: 
Journal:  Pathol Int       Date:  2000-09       Impact factor: 2.534

Review 5.  Extranodal NK/T-cell lymphoma: diagnosis and treatment cues.

Authors:  Ritsuro Suzuki; Kengo Takeuchi; Koichi Ohshima; Shigeo Nakamura
Journal:  Hematol Oncol       Date:  2008-06       Impact factor: 5.271

6.  Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia.

Authors:  Motoko Yamaguchi; Ritsuro Suzuki; Yok-Lam Kwong; Won Seog Kim; Yuichi Hasegawa; Koji Izutsu; Junji Suzumiya; Takayuki Okamura; Shigeo Nakamura; Keisei Kawa; Kazuo Oshimi
Journal:  Cancer Sci       Date:  2008-02-19       Impact factor: 6.716

7.  P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833.

Authors:  M Egashira; N Kawamata; K Sugimoto; T Kaneko; K Oshimi
Journal:  Blood       Date:  1999-01-15       Impact factor: 22.113

8.  Angiocentric T-cell and NK/T-cell lymphomas: radiotherapeutic viewpoints.

Authors:  Woong Sub Koom; Eun Ji Chung; Woo-Ick Yang; Su Jung Shim; Chang Ok Suh; Jae Kyung Roh; Joo-Heon Yoon; Gwi Eon Kim
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-07-15       Impact factor: 7.038

9.  Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality.

Authors:  Michael M C Cheung; John K C Chan; Wai-hon Lau; Roger K C Ngan; William W L Foo
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-09-01       Impact factor: 7.038

10.  Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211.

Authors:  Motoko Yamaguchi; Kensei Tobinai; Masahiko Oguchi; Naoki Ishizuka; Yukio Kobayashi; Yasushi Isobe; Kenichi Ishizawa; Nobuo Maseki; Kuniaki Itoh; Noriko Usui; Izumi Wasada; Tomohiro Kinoshita; Koichi Ohshima; Yoshihiro Matsuno; Takashi Terauchi; Shigeru Nawano; Satoshi Ishikura; Yoshikazu Kagami; Tomomitsu Hotta; Kazuo Oshimi
Journal:  J Clin Oncol       Date:  2009-10-05       Impact factor: 44.544

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.